Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers

Abstract

Aberrant CpG methylations play important roles in cancer development and progression. In this study, aberrant methylations in human breast cancer were searched for using methylation-sensitive representational difference analysis (MS-RDA). A CpG island (CGI) in the 5′ region of the heparan sulfate D -glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) gene was found to be hypermethylated, while its exon 2 was hypomethylated. In seven breast cancer cell lines, hypermethylation of the 5′ region and loss of 3-OST-2 expression were observed. Treatment with a demethylating agent, 5-aza-2′-deoxycytidine, removed the methylation of the CGI in the 5′ region and restored its expression, demonstrating silencing of the 3-OST-2 gene. Methylation-specific PCR (MSP) analysis in 85 primary breast cancers showed that the hypermethylation of the CGI in the 5′ region was present in 75 (88%) of them. Quantitative reverse transcriptase-PCR (RT–PCR) analysis in 37 primary breast cancers showed that the average expression level was decreased in them. Further, MSP analysis in primary colon, lung and pancreatic cancers showed that hypermethylation of the CGI in the 5′ region was present in the colon (8/10, 80%), lung (7/10, 70%) and pancreatic (10/10, 100%) cancers. These results showed that silencing of 3-OST-2 was present in a wide range of human cancers. The 3-OST-2 gene encodes an enzyme involved in the final modification step of heparan sulfate proteoglycans (HSPGs), and its silencing is expected to result in abnormal modification of HSPGs and abnormal signal transduction. From the high incidence, silencing of the 3-OST-2 gene is expected to have high diagnostic, and potentially therapeutic, values.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Asada K, Miyamoto K, Fukutomi T, Tsuda H, Yagi Y, Wakazono K, Oishi S, Fukui H, Sugimura T and Ushijima T . Oncology (in press).

  • Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG . (2001). Hum. Mol. Genet., 10, 687–692.

  • Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J and Zako M . (1999). Annu. Rev. Biochem., 68, 729–777.

  • Bird A . (2002). Genes Dev., 16, 6–21.

  • Clark SJ, Harrison J, Paul CL and Frommer M . (1994). Nucleic Acids Res., 22, 2990–2997.

  • Clark SJ and Melki J . (2002). Oncogene, 21, 5380–5387.

  • Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV and Laird PW . (2000). Nucleic Acids Res., 28, E32.

  • Esko JD and Lindahl U . (2001). J. Clin. Invest., 108, 169–173.

  • Esteller M, Corn PG, Baylin SB and Herman JG . (2001). Cancer Res., 61, 3225–3229.

  • Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB and Herman JG . (1999). Cancer Res., 59, 67–70.

  • Feinberg AP . (2001). Nat. Genet., 27, 9–10.

  • Gardiner-Garden M and Frommer M . (1987). J. Mol. Biol., 196, 261–282.

  • Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT and Jones PA . (1998). Cancer Res., 58, 1245–1252.

  • Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA., 93, 9821–9826.

  • Jones PA . (1999). Trends Genet., 15, 34–37.

  • Jones PA and Baylin SB . (2002). Nat. Rev. Genet., 3, 415–428.

  • Jones PA and Laird PW . (1999). Nat. Genet., 21, 163–167.

  • Kaneda A, Kaminishi M, Nakanishi Y, Sugimura T and Ushijima T . (2002). Int. J. Cancer, 100, 57–62.

  • Kaneda A, Kaminishi M, Yanagihara K, Sugimura T and Ushijima T . Cancer Res. (in press).

  • Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV and Meltzer SJ . (2000). J. Natl. Cancer Inst., 92, 1805–1811.

  • Kelsey G, Bodle D, Miller HJ, Beechey CV, Coombes C, Peters J and Williamson CM . (1999). Genomics, 62, 129–138.

  • Lisitsyn N, Lisitsyn N and Wigler M . (1993). Science, 259, 946–951.

  • Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD and Korc M . (2001). Cancer Res., 61, 5562–5569.

  • Muller K, Heller H and Doerfler W . (2001). J. Biol. Chem., 276, 14271–14278.

  • Perrimon N and Bernfield M . (2000). Nature, 404, 725–728.

  • Rein T, Zorbas H and DePamphilis ML . (1997). Mol. Cell. Biol., 17, 416–426.

  • Sambrook J, Fritsch EF and Maniatis T . (eds). (1989). Molecular Cloning, Vol. 2. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, pp 1914–1923.

    Google Scholar 

  • Shapiro B, Chakrabarty M, Cohn EM and Leon SA . (1983). Cancer, 51, 2116–2120.

  • Shworak NW, Liu J, Petros LM, Zhang L, Kobayashi M, Copeland NG, Jenkins NA and Rosenberg RD . (1999). J. Biol. Chem., 274, 5170–5184.

  • Silva JM, Dominguez G, Villanueva MJ, Gonzalez R, Garcia JM, Corbacho C, Provencio M, Espana P and Bonilla F . (1999). Br. J. Cancer, 80, 1262–1264.

  • Stanley MJ, Stanley MW, Sanderson RD and Zera R . (1999). Am. J. Clin. Pathol., 112, 377–383.

  • Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C and Beljanski M . (1989). Oncology, 46, 318–322.

  • Surani MA . (2001). Nature, 414, 122–128.

  • Takai D, Yagi Y, Wakazono K, Ohishi N, Morita Y, Sugimura T and Ushijima T . (2001). Oncogene, 20, 7505–7513.

  • Ushijima T, Morimura K, Hosoya Y, Okonogi H, Tatematsu M, Sugimura T and Nagao M . (1997). Proc. Natl. Acad. Sci. USA., 94, 2284–2289.

Download references

Acknowledgements

We are grateful to Dr Masatsugu Yano for providing tumor samples. This study was supported by Grants-in-Aid for the second term 10-year Comprehensive Strategy for Cancer Control and for Human Genome and Tissue Regeneration from the Ministry of Health, Labour, and Welfare, Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Toshikazu Ushijima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyamoto, K., Asada, K., Fukutomi, T. et al. Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 22, 274–280 (2003). https://doi.org/10.1038/sj.onc.1206146

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206146

Keywords

This article is cited by

Search

Quick links